Business
Olema Oncology Announces Two Poster Presentations at the San Antonio Breast Cancer Symposium 2020
SAN FRANCISCO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused
About this update from Olema Pharmaceuticals, Inc.
[{"type":"text","content":"SAN FRANCISCO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced two posters relating to OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), will be presented at the San Antonio Breast Cancer Symposium (SABCS), to be held virtually from December 8-11, 2020.\n The accepted abstracts cover a preclinical study evaluating the effects of OP-1250 in xenograft models and the protocol for a Phase 1/2 open-label, first-in-human, multicenter, dose escalation and dose expansion study evaluating OP-1250 monotherapy in adult subjects with locally advanced, recurrent, and metastatic Hormone Receptor (HR)-positive, human epidermal growth factor receptor 2 negative (HER2-) breast cancer. The accepted abstracts are now available online through the SABCS conference website. Details are as follows: Olema Poster Presentations Session: 18 – Tumor Biology IIIPoster #: PS18-16Abstract #: 1410Title: The Complete Estrogen Receptor Antagonist OP-1250 Shrinks Tumors in Xenograft Models and Has Favorable Preclinical Pharmacokinetic AttributesSession Date & Time: Wednesday, December 9, 2020; 8:00 a.m. CT Session: Ongoing Trials – Endocrine TherapyPoster #: OT-09-10Abstract #: 1167Title: A Phase I/II Open-label, First-in-Human, Multicenter, Dose Escalation and Dose Expansion Study of OP-1250 Monotherapy in Adult Subjectswith Locally Advanced, Recurrent, and Metastatic Hormone Receptor (HR)-Positive, HER2-Negative Breast Cancer Session Date & Time: Wednesday, December 9, 2020; 8:00 a.m. CT About Olema OncologyOlema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is an orally available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer. Olema is hea...